MRK Merck & Co Inc

Price (delayed)

$78.33

Market cap

$198.28B

P/E Ratio

35.6

Dividend/share

$2.6

EPS

$2.2

Enterprise value

$216.23B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the ...

Highlights
Merck's equity has increased by 24% from the previous quarter and by 20% YoY
MRK's debt is down by 15% since the previous quarter and by 14% year-on-year
The P/E is 29% higher than the last 4 quarters average of 27.7 but 14% lower than the 5-year quarterly average of 41.5
MRK's quick ratio is up by 29% since the previous quarter but it is down by 11% year-on-year
The EPS has contracted by 47% YoY and by 21% from the previous quarter
The net income has declined by 47% year-on-year and by 21% since the previous quarter

Key stats

What are the main financial stats of MRK
Market
Shares outstanding
2.53B
Market cap
$198.28B
Enterprise value
$216.23B
Valuations
Price to earnings (P/E)
35.6
Price to book (P/B)
5.96
Price to sales (P/S)
4.09
EV/EBIT
31.2
EV/EBITDA
20.98
EV/Sales
4.45
Earnings
Revenue
$48.55B
EBIT
$6.93B
EBITDA
$10.31B
Free cash flow
$5.36B
Per share
EPS
$2.2
Free cash flow per share
$2.12
Book value per share
$13.15
Revenue per share
$19.17
TBVPS
$22.98
Balance sheet
Total assets
$90.69B
Total liabilities
$57.3B
Debt
$26.52B
Equity
$33.29B
Working capital
$6.76B
Liquidity
Debt to equity
0.8
Current ratio
1.31
Quick ratio
0.75
Net debt/EBITDA
1.74
Margins
EBITDA margin
21.2%
Gross margin
67.5%
Net margin
11.5%
Operating margin
11.3%
Efficiency
Return on assets
6.1%
Return on equity
19.4%
Return on invested capital
12.8%
Return on capital employed
10.1%
Return on sales
14.3%
Dividend
Dividend yield
3.32%
DPS
$2.6
Payout ratio
118.2%

MRK stock price

How has the Merck stock price performed over time
Intraday
0%
1 week
-2.85%
1 month
7.58%
1 year
-0.92%
YTD
-4.24%
QTD
4.29%

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$48.55B
Gross profit
$32.76B
Operating income
$5.5B
Net income
$5.57B
Gross margin
67.5%
Net margin
11.5%
Merck's operating margin has shrunk by 54% YoY and by 16% QoQ
Merck's operating income has plunged by 51% YoY and by 12% from the previous quarter
MRK's net margin is down by 50% year-on-year and by 24% since the previous quarter
The net income has declined by 47% year-on-year and by 21% since the previous quarter

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
P/E
35.6
P/B
5.96
P/S
4.09
EV/EBIT
31.2
EV/EBITDA
20.98
EV/Sales
4.45
The EPS has contracted by 47% YoY and by 21% from the previous quarter
The P/E is 29% higher than the last 4 quarters average of 27.7 but 14% lower than the 5-year quarterly average of 41.5
Merck's equity has increased by 24% from the previous quarter and by 20% YoY
The price to book (P/B) is 16% lower than the last 4 quarters average of 7.1 and 5% lower than the 5-year quarterly average of 6.3
MRK's P/S is 7% below its 5-year quarterly average of 4.4 and 4.9% below its last 4 quarters average of 4.3
The revenue has grown by 6% YoY and by 4.4% from the previous quarter

Efficiency

How efficient is Merck business performance
Merck's ROE has plunged by 51% YoY and by 25% from the previous quarter
The ROIC has shrunk by 50% YoY and by 17% QoQ
The company's return on assets has shrunk by 50% YoY and by 21% QoQ
The ROS has contracted by 47% YoY and by 20% from the previous quarter

Dividends

What is MRK's dividend history
DPS
$2.6
Dividend yield
3.32%
Payout ratio
118.2%
Recent dividends

Financial health

How did Merck financials performed over time
The total assets is 58% more than the total liabilities
MRK's quick ratio is up by 29% since the previous quarter but it is down by 11% year-on-year
The current ratio has grown by 28% from the previous quarter
MRK's debt is 20% smaller than its equity
The debt to equity has contracted by 31% from the previous quarter and by 29% YoY
Merck's equity has increased by 24% from the previous quarter and by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.